Skip to main content

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Aaron Lisberg, MD, On Treatment Approaches for Oncogene-Driven NSCLC

 

Dr Lisberg discusses when to use checkpoint inhibitor therapy in patients with targetable mutations in non–small-cell lung cancer (NSCLC), a recap of his presentation at the virtual 2020 Personalized Therapies in Thoracic Oncology meeting.

Advertisement

Advertisement

Advertisement

Advertisement